ReviewTherapeutic advances in medical oncology2020
Genetic aberrations and molecular biology of cardiac sarcoma.
Review in Therapeutic advances in medical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 24 citations in OpenAlex.
- Multidisciplinary Management of a Rare Primary Cardiac Angiosarcoma.JACC. Case reports · 2026Article
- Cardiac intimal sarcoma presenting as basilar artery occlusion treated with tenecteplase and thrombectomy: a case report.Frontiers in cardiovascular medicine · 2026Article
- Primary cardiac myxofibrosarcoma: a case description and literature review of a highly rare entity.Quantitative imaging in medicine and surgery · 2026Article
- Genetic Heterogeneity of Undifferentiated Pleomorphic Sarcoma: Is There Potential for Targeted Therapy?Cancers · 2025Review
- Case report of an aggressive cardiac myxofibrosarcoma with rapid disease progression.European heart journal. Case reports · 2025Article
- A Comprehensive Review of Cardiac Tumors: Imaging, Pathology, Treatment, and Challenges in the Third Millennium.Diagnostics (Basel, Switzerland) · 2025Review
- Diagnosis and treatment of cardiac tumors.Medical oncology (Northwood, London, England) · 2025Review
- Primary Cardiac Myxofibrosarcoma of the Left Atrium with Heterologous Elements Mimicking a Cardiac Myxoma.The American journal of case reports · 2025Article
- Complexity in interpreting cardiac valve-associated thrombus from tumors in Li-Fraumeni syndrome.World journal of clinical cases · 2024Article
- Cardiac Tumors: Review.Brazilian journal of cardiovascular surgery · 2024Review
- Primary cardiac sarcoma: demographics, genomic study correlation, and survival benefits of surgery with adjuvant therapy in U.S. population.Clinical research in cardiology : official journal of the German Cardiac Society · 2024Article
- Cardiac Magnetic Resonance to Predict Cardiac Mass Malignancy: The CMR Mass Score.Circulation. Cardiovascular imaging · 2024Observational
- Cadonilimab plus anlotinib effectively relieve rare cardiac angiosarcoma with multiple metastases: a case report and literature review.Clinical research in cardiology : official journal of the German Cardiac Society · 2024Review
- Genomic Landscape Comparison of Cardiac versus Extra-Cardiac Angiosarcomas.Biomedicines · 2023Article
- Primary Cardiac Angiosarcoma: A Review.Cureus · 2023Review
- Genomic Characterization of Rare Primary Cardiac Sarcoma Entities.Diagnostics (Basel, Switzerland) · 2023Article
- Interactions Networks for Primary Heart Sarcomas.Cancers · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiac tumors are rare and complex entities. Early assessment and differentiation between non-neoplastic and neoplastic masses, be they benign or malignant, is essential for guiding diagnosis, determining prognosis, and planning therapy. Cardiac sarcomas represent the most frequent primary malignant histotype. They could have manifold presentations so that the diagnosis is often belated. Moreover, considering their rarity and the limitation due to the cardiac location itself, the optimal multimodal management of patients affected by primary cardiac sarcomas still remains highly difficult and outcome dismal. Therefore, there is an urgent need to improve these results mainly focusing on more adequate tools for prompt diagnosis and exploring new and more effective therapies. Knowledge about the molecular landscape and pathogenesis of cardiac sarcoma is even more limited due to the rarity of this disease. In this sense, the molecular characterization of heart tumors could unfold potentially novel, druggable targets. In this review, we focused on genetic aberrations and molecular biology of cardiac sarcomas, collecting the scarce information available and resuming all the molecular findings discovered in each tumor subtype, with the aim to get further insights on mechanisms involved in tumor growth and to possibly highlight specific molecular profiles that can be used as diagnostic tests and unveil new clinically actionable targets in this tricky and challenging disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.